莫西沙星联合匹多莫德治疗老年呼吸道感染患者的效果及细胞免疫指标评估 : = Effect of pidotimod on respiratory tract infection in elderly patients and evaluation of cellular immune indicators
目的评估老年呼吸道感染患者应用莫西沙星联合匹多莫德治疗的效果及对细胞免疫指标的影响。方法选取84例老年呼吸道感染患者,根据不同治疗方案纳入A组(42例)与B组(42例)。A组应用莫西沙星治疗,B组应用莫西沙星联合匹多莫德治疗,对比两组的治疗效果、临床症状改善时间(发热、肺啰音、咳嗽咳痰)、细胞免疫指标(CD4~+、CD8~+、CD4~+/CD8~+)以及血清炎性因子水平[白细胞介素(IL)-6、IL-8及肿瘤坏死因子-α(TNF-α)]。结果 B组的总有效率(95.24%)高于A组(80.95%),P<0.05;B组发热、肺啰音、咳嗽咳痰的改善时间[(2.84±0.23)d、(4.11±0.40)d、(3.51±0.62)d]均短于A组[(3.91±0.36)d、(5.25±0.56)d、(4.76±0.83)d],P均<0.05;B组治疗后的CD4~+、CD8~+、CD4~+/CD8~+[(42.16±6.53)%、(27.15±3.96)%、1.84±0.79]均优于A组[(35.87±4.21)%、(32.82±4.11)%、1.36±0.53],P均<0.05;B组治疗后的IL-6、IL-8、TNF-α[(72.89±64.36)ng/L、(162.37±105.91)ng/L、(107.86±59.62)μg/L]均低于A组[(159.66±75.80)ng/L、(385.84±142.68)ng/L、(189.44±76.56)μg/L],P均<0.05。结论老年呼吸道感染患者应用莫西沙星联合匹多莫德治疗的效果显著,可有效消除患者的临床症状,且可改善免疫功能指标,降低血清炎性因子水平。.
Objective To evaluate the effect of Pidotimod on cellular immunity in elderly patients with respiratory tract infection.Methods 84 elderly patients with respiratory tract infection diagnosed clinically were enrolled in group A(42 cases) and group B(42 cases) according to different treatment schemes.Group A was treated with moxifloxacin and group B was treated with moxifloxacin combined with pidotimod.The therapeutic effect,improvement time of clinical symptoms(fever,lung rale,cough and sputum),cellular immunity,epidemic indicators(CD4~+,CD8~+,CD4~+/CD8~+),and serum levels of inflammatory factors(IL-6,IL-8,TNF-alpha) in two groups were compared.Results The total effective rate of group B(95.24%) was higher than that of group A(80.95%),P<0.05;the improvement time of fever,lung rale,cough and sputum in group B [(2.84±0.23)d,(4.11±0.40)d,(3.51±0.62)d] was shorter than that in group A [(3.91±0.36)d,(5.25±0.56)d,(4.76±0.83)d],P<0.05;CD4~+,CD8~+,CD4~+/CD8~+ in group B [(42.16±6.53)%,(27.15±3.96)%,1.84±0.79] were better than those in group A [(35.87±4.21)%,(32.82±4.11)%,(1.36±0.53)],P<0.05;the levels of IL-6,IL-8 and TNF-a in group B [(72.89±64.36)ng/L,(162.37±105.91)ng/L,(107.86±59.62)μg/L] were lower than those in group A [(159.66±75.80)ng/L,(385.84±142.68)ng/L,(189.44±76.56)μg/L],P<0.05.Conclusion Pidotimod is effective in the treatment of elderly patients with respiratory tract infection,and can effectively eliminate clinical symptoms,improve immune function and reduce the level of serum inflammatory factors..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019-12-27 13:55 2019 |
|---|---|
| Erschienen: |
2019-12-27 13:55 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2019 |
|---|---|
| Enthalten in: |
Zhong guo lin chuang bao jian za zhi - (2019), 06 vom: 27 13:55. Dez., Seite 814-817 Original Letters: Enthalten in 中国临床保健杂志 (DE-600)2991025-0 (DE-600)2991025-0 安徽省合肥市 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Effect of pidotimod on respiratory tract infection in elderly patients and evaluation of cellular immune indicators |
|---|
| Beteiligte Personen: |
孔一名 [VerfasserIn] |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Themen: |
免疫,细胞 |
|---|
| Anmerkungen: |
Author info:Kong Yiming;Wang Xiaomi;Li Xiaobo;Guo Weiwei;Huang Maomao;Zhang Tianwei;Respiratory and Intensive Care Unit,the First People′s Hospital of Taizhou |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ647366177 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ647366177 | ||
| 003 | DE-627 | ||
| 005 | 20230121131828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230104s2019 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ647366177 | ||
| 035 | |a (SBB-XA)CAJ_LZBJ201906024 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R56 |2 clc | ||
| 100 | 0 | |a 孔一名 |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 莫西沙星联合匹多莫德治疗老年呼吸道感染患者的效果及细胞免疫指标评估 |b = Effect of pidotimod on respiratory tract infection in elderly patients and evaluation of cellular immune indicators |
| 246 | 3 | 1 | |a Effect of pidotimod on respiratory tract infection in elderly patients and evaluation of cellular immune indicators |
| 264 | 1 | |c 2019-12-27 13:55 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:Kong Yiming;Wang Xiaomi;Li Xiaobo;Guo Weiwei;Huang Maomao;Zhang Tianwei;Respiratory and Intensive Care Unit,the First People′s Hospital of Taizhou | ||
| 520 | |a 目的评估老年呼吸道感染患者应用莫西沙星联合匹多莫德治疗的效果及对细胞免疫指标的影响。方法选取84例老年呼吸道感染患者,根据不同治疗方案纳入A组(42例)与B组(42例)。A组应用莫西沙星治疗,B组应用莫西沙星联合匹多莫德治疗,对比两组的治疗效果、临床症状改善时间(发热、肺啰音、咳嗽咳痰)、细胞免疫指标(CD4~+、CD8~+、CD4~+/CD8~+)以及血清炎性因子水平[白细胞介素(IL)-6、IL-8及肿瘤坏死因子-α(TNF-α)]。结果 B组的总有效率(95.24%)高于A组(80.95%),P<0.05;B组发热、肺啰音、咳嗽咳痰的改善时间[(2.84±0.23)d、(4.11±0.40)d、(3.51±0.62)d]均短于A组[(3.91±0.36)d、(5.25±0.56)d、(4.76±0.83)d],P均<0.05;B组治疗后的CD4~+、CD8~+、CD4~+/CD8~+[(42.16±6.53)%、(27.15±3.96)%、1.84±0.79]均优于A组[(35.87±4.21)%、(32.82±4.11)%、1.36±0.53],P均<0.05;B组治疗后的IL-6、IL-8、TNF-α[(72.89±64.36)ng/L、(162.37±105.91)ng/L、(107.86±59.62)μg/L]均低于A组[(159.66±75.80)ng/L、(385.84±142.68)ng/L、(189.44±76.56)μg/L],P均<0.05。结论老年呼吸道感染患者应用莫西沙星联合匹多莫德治疗的效果显著,可有效消除患者的临床症状,且可改善免疫功能指标,降低血清炎性因子水平。 | ||
| 520 | |a Objective To evaluate the effect of Pidotimod on cellular immunity in elderly patients with respiratory tract infection.Methods 84 elderly patients with respiratory tract infection diagnosed clinically were enrolled in group A(42 cases) and group B(42 cases) according to different treatment schemes.Group A was treated with moxifloxacin and group B was treated with moxifloxacin combined with pidotimod.The therapeutic effect,improvement time of clinical symptoms(fever,lung rale,cough and sputum),cellular immunity,epidemic indicators(CD4~+,CD8~+,CD4~+/CD8~+),and serum levels of inflammatory factors(IL-6,IL-8,TNF-alpha) in two groups were compared.Results The total effective rate of group B(95.24%) was higher than that of group A(80.95%),P<0.05;the improvement time of fever,lung rale,cough and sputum in group B [(2.84±0.23)d,(4.11±0.40)d,(3.51±0.62)d] was shorter than that in group A [(3.91±0.36)d,(5.25±0.56)d,(4.76±0.83)d],P<0.05;CD4~+,CD8~+,CD4~+/CD8~+ in group B [(42.16±6.53)%,(27.15±3.96)%,1.84±0.79] were better than those in group A [(35.87±4.21)%,(32.82±4.11)%,(1.36±0.53)],P<0.05;the levels of IL-6,IL-8 and TNF-a in group B [(72.89±64.36)ng/L,(162.37±105.91)ng/L,(107.86±59.62)μg/L] were lower than those in group A [(159.66±75.80)ng/L,(385.84±142.68)ng/L,(189.44±76.56)μg/L],P<0.05.Conclusion Pidotimod is effective in the treatment of elderly patients with respiratory tract infection,and can effectively eliminate clinical symptoms,improve immune function and reduce the level of serum inflammatory factors. | ||
| 610 | 2 | 4 | |a 浙江台州市第一人民医院呼吸与危重症医学科 |
| 650 | 4 | |a 呼吸系及胸部疾病 | |
| 650 | 4 | |a 内科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a Disease of Respiratory System | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a 呼吸道感染 | |
| 650 | 4 | |a 抗菌药 | |
| 650 | 4 | |a 免疫,细胞 | |
| 650 | 4 | |a 老年人 | |
| 650 | 4 | |a Respiratory tract infections | |
| 650 | 4 | |a Anti-bacterial agents | |
| 650 | 4 | |a Immunity,cellular | |
| 650 | 4 | |a Aged | |
| 700 | 0 | |a 王笑咪 |4 oth | |
| 700 | 0 | |a 李小波 |4 oth | |
| 700 | 0 | |a 郭微微 |4 oth | |
| 700 | 0 | |a 黄茂 |4 oth | |
| 700 | 0 | |a 张添威 |4 oth | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t Zhong guo lin chuang bao jian za zhi |d An hui sheng he fei shi, 1998 |g (2019), 06 vom: 27 13:55. Dez., Seite 814-817 |h Online-Ressource |w (DE-627)CAJ111149347 |w (DE-600)2991025-0 |7 nnns |
| 773 | 1 | 8 | |g year:2019 |g number:06 |g day:27 13:55 |g month:12 |g pages:814-817 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=LZBJ201906024 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=LZBJ201906024 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |t 中国临床保健杂志 |d 安徽省合肥市 |h Online-Ressource |w (DE-627)CAJ111149347 |w (DE-600)2991025-0 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2019 |e 06 |b 27 13:55 |c 12 |h 814-817 |
| 951 | |a AR | ||
| 952 | |j 2019 |e 06 |b 27 13:55 |c 12 |h 814-817 | ||
| 980 | |2 11 |1 01 |x 0001 |b 666870845 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 04-01-23 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=LZBJ201906024 | ||